Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.

Abstract

Recently, pemafibrate and a low-carbohydrate diet (LCD) have each been reported to improve fatty liver disease. However, it is unclear whether their combination improves fatty liver disease and is equally effective in obese and non-obese patients. In 38 metabolic-associated fatty liver disease (MAFLD) patients, classified by baseline body mass index (BMI), changes in laboratory values, magnetic resonance elastography (MRE), and magnetic resonance imaging-proton density fat fraction (MRI-PDFF) were studied after 1year of combined pemafibrate plus mild LCD. The combination treatment resulted in weight loss (P=0.002), improvement in hepatobiliary enzymes (γ-glutamyl transferase, P=0.027; aspartate aminotransferase, P<0.001; alanine transaminase [ALT], P<0.001), and improvement in liver fibrosis markers (FIB-4 index, P=0.032; 7s domain of type IV collagen, P=0.002; M2BPGi, P<0.001). Vibration-controlled transient elastography improved from 8.8 to 6.9kPa (P<0.001) and MRE improved from 3.1 to 2.8kPa (P=0.017) in the liver stiffness. MRI-PDFF improved from 16.6% to 12.3% in liver steatosis (P=0.007). In patients with a BMI of 25 or higher, improvements of ALT (r=0.659, P<0.001) and MRI-PDFF (r=0.784, P<0.001) were significantly correlated with weight loss. However, in patients with a BMI below 25, the improvements of ALT or PDFF were not accompanied by weight loss. Combined treatment with pemafibrate and a low-carbohydrate diet resulted in weight loss and improvements in ALT, MRE, and MRI-PDFF in MAFLD patients. Although such improvements were associated with weight loss in obese patients, the improvements were observed irrespective of weight loss in non-obese patients, indicating this combination can be effective both in obese and non-obese MAFLD patients.